Clinical trials: Tumor Immunity
Breast Neoplasms
Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer
The aim of this prospective, randomized, multicenter, open-label, explorative phase II study is to identify the impact of (neo)adjuvant denosumab on the systemic immunity and local immunologic microenvironment in postmenopausal…
- Trial name
- PERIDENO (NCT03532087)
- Testing
- Denosumab 120 mg, Denosumab 60 mg
- Where
- 8 sites in Netherlands
- Sponsor
- Borstkanker Onderzoek Groep
Multiple Myeloma, Myeloma, Multiple
Study of the Immune Response After Vaccination in Multiple Myeloma Patients
This study will collect blood samples from healthy volunteers and volunteers with multiple myeloma who are going to get the seasonal flu, pneumonia, haemophilus influenzae B (HIB), and/or meningococcus vaccines.
- Conditions
- Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
- Trial name
- NCT02294487
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Infections, Papillomavirus
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. The infection of the cervix by certain oncogenic types of HPV, if not cleared, can lead to cervical cancer in women.
- Trial name
- NCT00485732
- Testing
- HPV-16/18 VLP/AS04 vaccine (Cervarix TM)
- Where
- 6 sites in South Korea
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Metastatic Malignant Melanoma
Inducing Systemic Immunity and Regressions in Metastatic Melanoma
In patients with multiple metastatic nodules of melanoma, the investigators evaluated whether autologous cytokines injected into cutaneous metastases would induce a systemic immune response as evidenced by the accumulation of…
- Trial name
- NCT02350972
- Testing
- Autologous cytokines
- Volunteers
- 88 people
- Sponsor
- NYU Langone Health
Colorectal Cancer, Breast Cancer
Impact of Aerobic Exercise on the Anticancer Immune Response in Patients Receiving Cancer Treatment
The goal of this clinical trial is to determine to what extent anticancer immune cells mobilized by aerobic exercise exhibit migratory and functional capacity towards cancer cells in patients undergoing treatment for breast or…
- Conditions
- Colorectal Cancer, Breast Cancer, Non Metastatic Cancer
- Trial name
- Immuno-Ex (NCT06911970)
- Testing
- Exercise
- Where
- 2 sites in Canada
- Volunteers
- 44 people
- Sponsor
- Université de Sherbrooke
Stage IV Pancreatic Cancer
VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer
First-in-human phase I dose escalation study in patients with locally advanced, inoperable and stage IV pancreatic cancer to examine safety, tolerability, and immune response to the investigational VEGFR-2 DNA vaccine VXM01 to…
- Trial name
- NCT01486329
- Testing
- VXM01
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Vaximm GmbH
Lymphoma
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004197
- Testing
- keyhole limpet hemocyanin, sargramostim, tumor cell-based vaccine therapy
- Where
- 2 sites in United States
- Sponsor
- University of Nebraska
Tumor Immunity
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor
68Ga-DOTA-dPNE PET/CT imaging was performed on patients with malignant tumors to observe the binding of lesions with the tracer and evaluate the expression of CD73.
- Trial name
- NCT06844110
- Testing
- 68GA-DOTA-dPNE
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Neoplasms
Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection
According to a survey from Department of Health in 2004, cancer has been the leading cause of death in the Taiwan area. In 2004, people died of cancer, accounting for 27.2 percent of all deaths.
- Trial name
- NCT00521287
- Testing
- Immune profiling and DC vaccine
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Mackay Memorial Hospital
COVID-19, Solid Tumor
National Project on Vaccines, COVID-19 and Frail Patients
This is a multicentre observational study with the aim of evaluating the antibody and cellular response after vaccination for SARS-CoV-2 with Pfizer-BioNTech or Moderna vaccines in frail subjects with impaired immuno-competence…
- Conditions
- COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder
- Trial name
- VAX4FRAIL (NCT04848493)
- Testing
- COVID-19 vaccines
- Where
- 12 sites in Italy
- Volunteers
- 747 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Non Small Cell Lung Cancer, Bladder Cancer
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Non-small cell lung cancer (NSCLC) is the most common histological form, accounting for 85% of all bronchopulmonary cancers (PBC).
- Conditions
- Non Small Cell Lung Cancer, Bladder Cancer, ENT Cancer
- Trial name
- CINECI (NCT04487457)
- Testing
- Blood samples
- Where
- 2 sites in France
- Volunteers
- 31 people
- Sponsor
- University Hospital, Tours
Melanoma
Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
The goals of this study are to 1) assess the safety of recombinant MAGE-A3 protein combined with AS15 Immunological Adjuvant System (recMAGE-A3 + AS15) as an Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) when…
- Trial name
- Mel55 (NCT01425749)
- Testing
- recMAGE-A3 + AS15 ASCI
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Craig L Slingluff, Jr
Breast Cancer
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating women with previously treated…
- Trial name
- NCT00706615
- Testing
- Ad-sig-hMUC-1/ecdCD40L vaccine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Multiple Myeloma (MM), CAR T Cells
BEAM-MM - β-Hydroxybutyrate-Enhanced Adaptive Immunity in Multiple Myeloma
This study investigates whether raising blood levels of beta-hydroxybutyrate (BHB) - a natural molecule produced by the body during fasting or a low-carbohydrate diet - is safe and feasible and can improve the effectiveness of…
- Conditions
- Multiple Myeloma (MM), CAR T Cells, Bispecific Antibodies
- Trial name
- BEAM-MM (NCT07564219)
- Testing
- Ketogenic diet, Ketogenic Drinks
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Surgery, Renal Cancer
Effects of Anesthesia on Immunity in Cancer
The aim of the study is a comparative study of the cellular immunity response of patients operated on for kidney cancer under total intravenous and inhalational anesthesia.
- Trial name
- NCT03514550
- Testing
- Propofol, Sevoflurane, Epidural block
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.
- Conditions
- Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome, Sézary
- Trial name
- NCT04960618
- Testing
- Gemcitabine, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Dysplasia
The Mother-Daughter Project: Merck-4
This project serves to continue a community-based initiative, known as the Kenya Mother-Daughter Cervical Cancer Eradication Project, or the Mother-Daughter Project (MDP), in the Webuye region of Western Kenya.
- Trial name
- Merck-4 (NCT07240220)
- Testing
- Gardisil-9, High Risk HPV DNA Testing, Visual Inspection with acetic acid (VIA) and possible cervical biopsy
- Where
- Kenya
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Indiana University
Cervical Cancer, Human Papilloma Virus
HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV
Our study will assess and measure population effectiveness of prophylactic HPV vaccine in reducing cervical, anal, and/or oral prevalent and 6-month persistent infections among HPV-vaccinated and 757 HPV-unvaccinated Rwandan WLWH…
- Conditions
- Cervical Cancer, Human Papilloma Virus, Human Immunodeficiency Virus, HPV-Related Carcinoma
- Trial name
- NCT05247853
- Testing
- Blood collection, Oral, cervicovaginal and anal specimen collection, Anoscopy & Biopsy of Acetowhite Lesions
- Where
- Rwanda
- Volunteers
- 3,127 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Molecular Classification of HNSCC
HNSCC Immuno-genomics Project
For locally advanced and recurrent / metastatic head \& neck squamous cell carcinoma (HNSCC), the is an unmet need for the development of efficient treatment combinations, particularly with immune checkpoint inhibitors.
- Trial name
- NCT06725342
- Testing
- Combined DNA/RNA sequencing on clinical FFPE material (technically challenging; innovative); immuno-genomics test.
- Volunteers
- 401 people
- Sponsor
- Hellenic Cooperative Oncology Group
Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how well it works in preventing Epstein-Barr virus (EBV) infection and…
- Conditions
- Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm
- Trial name
- NCT06741072
- Testing
- Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center